• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Do Rates of Ectopic Pregnancy Differ with Hormonal Contraceptive Method?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Kopp-Kallner et al. (Obstetrics & Gynecology, 2022) estimated the incidence rates for ectopic pregnancy by contraceptive method in a cohort of women using hormonal contraception

METHODS:

  • Population-based national registry study
    • 3 national Swedish registries: Prescribed Drug Register | National Patient Register | Medical Birth Register
  • Population
    • Women aged 15 to 49 years
    • With filled prescriptions for a hormonal contraceptive between 2005 and 2016
  • Exposures
    • Hormonal contraception method
  • Study design
    • For each individual, all exposed person-years were allocated to treatment episodes depending on the method of contraception
    • Treatment time
      • Started the day the prescription was filled
      • Ended on either the first day of the end of supply, new eligible dispensing, pregnancy-related diagnosis and its associated estimated last menstrual period, or removal procedure
    • Contraceptives
      • Hormonal IUDs | Combined hormonal contraceptives (patches, vaginal rings, pills) | Etonogestrel implants | Oral medium-dose progestogen-only | Oral low-dose progestogen-only | Medroxyprogesterone acetate injections 
    • Ectopic pregnancy defined based on ICD10 codes
    • Cox regression model used to adjust for confounders
      • Age | History of endometriosis | Previous ectopic pregnancy
  • Primary outcome
    • Incidence rates of ectopic pregnancy per 1,000 woman-years

RESULTS:

  • 1,663,242 women
    • Ectopic pregnancy: 1915
  • Incidence of ectopic pregnancy
    • General: 0.28 per 1,000 woman-years (95% CI, 0.26 to 0.29)
    • History of endometriosis: 0.25 per 1,000 women years (95% CI, 0.12 to 0.44)
    • History of ectopic pregnancy: 6.09 (95% CI, 4.88 to 7.50) per 1,000 woman-years
  • Incidence rates of ectopic pregnancy by method of hormonal contraception
    • 13.5-mg levonorgestrel (LNG) IUD
      • 2.76 (95% CI, 2.26 to 3.35) per 1,000 person-years
    • 52-mg LNG hormonal IUD
      • 0.30 (95% CI, 0.28 to 0.33) per 1,000 person-years
    • Combined oral contraception
      • 0.20 (95% CI, 0.19 to 0.22) per 1,000 person-years
    • Progestogen implants
      • 0.31 (95% CI, 0.26 to 0.37) per 1,000 person-years
    • Oral medium-dose progestogen (desogestrel 75 mg)
      • 0.24 (95% CI, 0.21 to 0.27) per 1,000 person-years
    • Oral low-dose progestogen (norethisterone 0.35 mg & lynestrenol 0.5 mg)
      • 0.81 (95% CI, 0.70 to 0.93) per 1,000 person-years

CONCLUSION:

  • Ectopic pregnancy incidence was lower in individuals using hormonal contraception vs the general population
  • Those using the 13.5-mg LNG IUD had an increased incidence of ectopic pregnancy, compared to other hormonal contraceptive methods, including the 52-mg LNG IUD
  • The authors state

Hormonal IUDs are user-friendly and safe to use, providing women with highly effective and reversible long-acting contraception with few side effects

The results of the current study indicate that the 13.5-mg LNG hormonal IUD should not be recommended for women who are concerned about the risk of ectopic pregnancy

Learn More – Primary Sources:

Method of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RCT Results: Active or Expectant Management for Persisting Pregnancy of Unknown Location?
Is Progestin-Based Contraception Linked to Depression?
Current Hormonal Contraception Methods and Breast Cancer Risk: Prospective Cohort Data

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site